Theriva Biologics, Inc.

NYSEAM:TOVX Stock Report

Market Cap: US$4.1m

Theriva Biologics Valuation

Is TOVX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of TOVX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate TOVX's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TOVX's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for TOVX?

Key metric: As TOVX is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for TOVX. This is calculated by dividing TOVX's market cap by their current book value.
What is TOVX's PB Ratio?
PB Ratio0.2x
BookUS$24.64m
Market CapUS$4.09m

Price to Book Ratio vs Peers

How does TOVX's PB Ratio compare to its peers?

The above table shows the PB ratio for TOVX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average1.1x
FRTX Fresh Tracks Therapeutics
0.4xn/aUS$4.2m
OGEN Oragenics
2.8xn/aUS$4.1m
SNPX Synaptogenix
0.3x-25.9%US$4.9m
NCNA NuCana
0.8x9.2%US$4.5m
TOVX Theriva Biologics
0.2x3.7%US$4.1m

Price-To-Book vs Peers: TOVX is good value based on its Price-To-Book Ratio (0.2x) compared to the peer average (1.1x).

Price to Book Ratio vs Industry

How does TOVX's PB Ratio compare vs other companies in the US Biotechs Industry?

64 CompaniesPrice / BookEstimated GrowthMarket Cap
Industry Avg.1.8x26.7%
TOVX Theriva Biologics
 0.2x3.7%US$4.09m
GRAL GRAIL
0.2x35.7%US$593.39m
SLRN Acelyrin
0.4x16.8%US$214.70m
TOVX 0.2xIndustry Avg. 1.8xNo. of Companies79PB01.63.24.86.48+
64 CompaniesEstimated GrowthMarket Cap
Industry Avg.1.8x26.7%
TOVX Theriva Biologics
 0.2x3.7%US$4.09m
No more companies

Price-To-Book vs Industry: TOVX is good value based on its Price-To-Book Ratio (0.2x) compared to the US Biotechs industry average (1.8x).

Price to Book Ratio vs Fair Ratio

What is TOVX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

TOVX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio0.2x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate TOVX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst TOVX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$1.45
US$90.50
+6,141.4%
93.4%US$175.00US$6.00n/a2
Jan ’26US$1.75
US$90.50
+5,071.4%
93.4%US$175.00US$6.00n/a2
Dec ’25US$1.44
US$90.50
+6,184.7%
93.4%US$175.00US$6.00n/a2
Nov ’25US$1.99
US$100.00
+4,925.1%
75.0%US$175.00US$25.00n/a2
Oct ’25US$1.28
US$100.00
+7,712.5%
75.0%US$175.00US$25.00n/a2
Sep ’25US$5.90
US$100.00
+1,594.9%
75.0%US$175.00US$25.00n/a2
May ’25US$10.15
US$112.50
+1,008.2%
55.6%US$175.00US$50.00n/a2
Apr ’25US$11.09
US$112.50
+914.9%
55.6%US$175.00US$50.00n/a2
Mar ’25US$12.37
US$112.50
+809.5%
55.6%US$175.00US$50.00n/a2
Feb ’25US$12.89
US$112.50
+772.8%
55.6%US$175.00US$50.00n/a2
Jan ’25US$10.75
US$112.50
+946.3%
55.6%US$175.00US$50.00US$1.752
Dec ’24US$15.00
US$112.50
+650.0%
55.6%US$175.00US$50.00US$1.442
Nov ’24US$11.13
US$112.50
+911.2%
55.6%US$175.00US$50.00US$1.992
Oct ’24US$13.48
US$112.50
+734.4%
55.6%US$175.00US$50.00US$1.282
Sep ’24US$12.87
US$112.50
+774.0%
55.6%US$175.00US$50.00US$5.902
Aug ’24US$16.25
US$137.50
+746.0%
27.3%US$175.00US$100.00US$5.462
Jul ’24US$25.00
US$137.50
+450.0%
27.3%US$175.00US$100.00US$6.032
Jun ’24US$15.98
US$137.50
+760.6%
27.3%US$175.00US$100.00US$6.252
May ’24US$15.98
US$137.50
+760.5%
27.3%US$175.00US$100.00US$10.152
Apr ’24US$17.46
US$137.50
+687.5%
27.3%US$175.00US$100.00US$11.092
Mar ’24US$21.62
US$137.50
+535.9%
27.3%US$175.00US$100.00US$12.372
Feb ’24US$23.25
US$137.50
+491.4%
27.3%US$175.00US$100.00US$12.892
Jan ’24US$11.37
US$137.50
+1,109.3%
27.3%US$175.00US$100.00US$10.752
Analyst Price Target
Consensus Narrative from 2 Analysts
US$90.50
Fair Value
98.4% undervalued intrinsic discount
2
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but there are not enough analysts covering the stock to determine statistical confidence in agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 20:15
End of Day Share Price 2025/01/08 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Theriva Biologics, Inc. is covered by 10 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
James MolloyAlliance Global Partners
Keay NakaeAscendiant Capital Markets LLC
Timothy ChiangBTIG